SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Shiba R.))
 

Sökning: (WFRF:(Shiba R.)) > First on-line surve...

First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias

Stefanutti, C. (författare)
D'Alessandri, G. (författare)
Petta, A. (författare)
visa fler...
Harada-Shiba, M. (författare)
Julius, U. (författare)
Soran, H. (författare)
Moriarty, P. M. (författare)
Romeo, Stefano, 1976 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Drogari, E. (författare)
Jaeger, B. R. (författare)
MightyMedic Multidisciplinary, Int (författare)
visa färre...
 (creator_code:org_t)
Elsevier BV, 2015
2015
Engelska.
Ingår i: Atherosclerosis Supplements. - : Elsevier BV. - 1567-5688. ; 18, s. 241-250
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The MightyMedic (Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsturbances Contrast) Working Group has been founded in 2013. The leading idea was to establish an international network of interdisciplinary nature aimed at working to cross national borders research projects, clinical trials, educational initiatives (meetings, workshops, summer schools) in the field of metabolic diseases, namely hyperlipidemias, and diabetes, preventive cardiology, and atherosclerosis. Therapeutic apheresis, its indications and techniques, is a parallel field of investigation. The first on-line survey of the Group has been completed in the first half of 2014. The survey included # 24 Centers in Italy, Germany, Greece, UK, Sweden, Japan and USA. Relevant data have been collected on current practice in diagnosis, therapy and follow-up of dyslipidemias. 240 subjects with hyperlipidemia and treated with lipoprotein apheresis have been reported in the survey, but a large percentage of patients (35%) who could benefit from this therapeutic option are still treated by conventional drug approach. Genetic molecular diagnosis is performed in only 33% of patients while Lipoprotein(a) (Lp(a)) is included in cardiovascular disease risk assessment in 71% of participating Centers. New detailed investigations and prospective multicenter studies are needed to evaluate changes induced by the impact of updated indications and strategies, as well as new treatment options, targeting standardization of therapeutic and diagnostic approaches.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Coronary artery disease
Dyslipidemia
Lipoprotein apheresis
Multicenter study
Survey
DENSITY-LIPOPROTEIN-APHERESIS
ASSOCIATION EXPERT PANEL
CORONARY-HEART-DISEASE
FAMILIAL HYPERCHOLESTEROLEMIA
ITALIAN REGISTRY
MANAGEMENT
GUIDELINES
SOCIETY
RECOMMENDATIONS
POPULATION
Peripheral Vascular Disease

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy